Levet is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalization in patients from 16 years of age with newly diagnosed epilepsy.
Levet is indicated as adjunctive therapy:
• In the treatment of partial-onset seizures with or without secondary generalization in adults and children with epilepsy.
• In the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy.
• In the treatment of primary generalized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalized epilepsy.
| Brand Name | LEVET |
|---|---|
| Strength | 100 mg/ml |
| Dosage Form | Oral Solution |
| Presentation | Bottle of 300 ml |
| Primary Packaging | Bottle |
| Specification | Type III glass + syringe |
| INN | Levetiracetam |
| VEIC Classification | Essential |
| Therapeutic Class | Neurology – Psychiatry |
| Subclass | Antiepileptics |
| Laboratory | SIMED |
| List / Schedule | A |
| Shelf Life | 24 months |
| Generic / Branded | Generic |
| MA Number | |
| MA Date | |
| Range | Neuro Psychiatry |
Reviews
There are no reviews yet.